[{"address1": "245 Main Street", "address2": "Second Floor", "city": "Cambridge", "state": "MA", "zip": "02142", "country": "United States", "phone": "617 500 8080", "website": "https://immuneering.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 currently in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.", "fullTimeEmployees": 67, "companyOfficers": [{"maxAge": 1, "name": "Dr. Benjamin J. Zeskind M.B.A., Ph.D.", "age": 41, "title": "Co-Founder, President, CEO & Director", "yearBorn": 1982, "fiscalYear": 2022, "totalPay": 898416, "exercisedValue": 0, "unexercisedValue": 374440}, {"maxAge": 1, "name": "Dr. Brett M. Hall Ph.D.", "age": 55, "title": "Chief Scientific Officer", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": 867917, "exercisedValue": 0, "unexercisedValue": 453376}, {"maxAge": 1, "name": "Ms. Mallory  Morales CPA", "age": 39, "title": "Principal Financial & Accounting Officer, Chief Accounting Officer and Treasurer", "yearBorn": 1984, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Paula  George CPA", "title": "Director of Accounting & Operations and Assistant Corporate Controller", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael D. Bookman J.D.", "age": 35, "title": "Chief Legal Officer & Secretary", "yearBorn": 1988, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Leah R. Neufeld", "age": 51, "title": "Chief People Officer", "yearBorn": 1972, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peter  King Ph.D.", "title": "Head of Discovery & VP", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Praveen  Nair Ph.D.", "title": "Head of Translational Pharmacology & VP", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Harold E. Brakewood", "age": 58, "title": "Chief Business Officer", "yearBorn": 1965, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephen  Sebastian CPA", "title": "Executive Director & Corporate Controller", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 6, "compensationRisk": 8, "shareHolderRightsRisk": 7, "overallRisk": 7, "governanceEpochDate": 1704067200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 6.71, "open": 6.7, "dayLow": 6.45, "dayHigh": 6.7299, "regularMarketPreviousClose": 6.71, "regularMarketOpen": 6.7, "regularMarketDayLow": 6.45, "regularMarketDayHigh": 6.7299, "beta": -0.755, "forwardPE": -3.2944162, "volume": 26509, "regularMarketVolume": 26509, "averageVolume": 67996, "averageVolume10days": 54790, "averageDailyVolume10Day": 54790, "bidSize": 1200, "askSize": 1000, "marketCap": 189956448, "fiftyTwoWeekLow": 3.7, "fiftyTwoWeekHigh": 14.29, "priceToSalesTrailing12Months": 417486.7, "fiftyDayAverage": 6.7748, "twoHundredDayAverage": 8.474575, "currency": "USD", "enterpriseValue": 97256736, "floatShares": 14911446, "sharesOutstanding": 29269100, "sharesShort": 2542407, "sharesShortPriorMonth": 2760024, "sharesShortPreviousMonthDate": 1700006400, "dateShortInterest": 1702598400, "sharesPercentSharesOut": 0.086899996, "heldPercentInsiders": 0.2761, "heldPercentInstitutions": 0.58055, "shortRatio": 33.22, "shortPercentOfFloat": 0.16229999, "impliedSharesOutstanding": 29269100, "bookValue": 3.554, "priceToBook": 1.8261114, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -51633692, "trailingEps": -1.86, "forwardEps": -1.97, "enterpriseToRevenue": 213751.06, "enterpriseToEbitda": -1.744, "52WeekChange": 0.3921162, "SandP52WeekChange": 0.19414937, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "IMRX", "underlyingSymbol": "IMRX", "shortName": "Immuneering Corporation", "longName": "Immuneering Corporation", "firstTradeDateEpochUtc": 1627651800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "e5829551-96d1-35fc-9c6d-d258079bf8f6", "messageBoardId": "finmb_308350677", "gmtOffSetMilliseconds": -18000000, "currentPrice": 6.49, "targetHighPrice": 25.0, "targetLowPrice": 10.0, "targetMeanPrice": 18.75, "targetMedianPrice": 20.0, "recommendationMean": 1.8, "recommendationKey": "buy", "numberOfAnalystOpinions": 8, "totalCash": 97242512, "totalCashPerShare": 3.322, "ebitda": -55756716, "totalDebt": 4542653, "quickRatio": 17.296, "currentRatio": 17.89, "totalRevenue": 455, "debtToEquity": 4.367, "returnOnAssets": -0.28323, "returnOnEquity": -0.45712003, "grossProfits": 158830, "freeCashflow": -31446908, "operatingCashflow": -48942048, "grossMargins": 1.0, "operatingMargins": -123287.71, "financialCurrency": "USD", "trailingPegRatio": null}]